title: Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution.
abstract: Last year, from the approximately 6,000 organ donors, only approximately 1,500 pancreata were used for clinical transplantation. Factors that contribute to this poor pancreas use include strict donor selection criteria and the requirement for short cold-ischemia time (CIT). Numerous pancreata have not been used because of long ischemia times postprocurement. Given the oxygen-rich environment of the islets in the native pancreas, it is conceivable that islets are highly susceptible to irreversible damage following prolonged ischemia. The use of continuously oxygenated perfluorohydrocarbons (PFCs), known for their high oxygen-solubility coefficients, in a two-layer culture with standard University of Wisconsin preservation media, has extended the acceptable range CIT, and, furthermore, there has been no evidence of adverse effects from PFCs on the outcome of transplanted cells, whereas they often enhance islet cell function. The purpose of this study was to use the two-layer culture method to improve donor-organ use from marginal donors. Fifteen organs were procured using the two-layer method, and 18 without using it, from donors greater than 50 years of age. Despite nonsignificant differences in age, weight of the donors, weight of the organ and CIT, the PFC group yielded an average of twofold more islet equivalents than those harvested from the control group. As a result, from the control group, only 2 of 18 organs were used for clinical islet transplantation, whereas 8 of 15 were used from the PFC group. To this end, the two-layer method may help clinicians overcome the problem of organ underuse.
authors.affiliation: Diabetes Research Institute, University of Miami School of Medicine, Florida 33136, USA. ricordi@miami.edu
authors.forename: Camillo
authors.initials: C
authors.lastname: Ricordi
authors.forename: Chris
authors.initials: C
authors.lastname: Fraker
authors.forename: Joel
authors.initials: J
authors.lastname: Szust
authors.forename: Ismail
authors.initials: I
authors.lastname: Al-Abdullah
authors.forename: Raffaella
authors.initials: R
authors.lastname: Poggioli
authors.forename: Topaz
authors.initials: T
authors.lastname: Kirlew
authors.forename: Aisha
authors.initials: A
authors.lastname: Khan
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Alejandro
mesh_terms: D000241:Adenosine / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000494:pharmacology*; D015925:Cryopreservation; D005466:Fluorocarbons / Q000494:pharmacology*; D005978:Glutathione / Q000494:pharmacology*; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D016381:Islets of Langerhans Transplantation; D008875:Middle Aged; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions; D010100:Oxygen / Q000378:metabolism; D011887:Raffinose / Q000494:pharmacology*; D014019:Tissue Donors
chemical_list: D005466:Fluorocarbons; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose; D010100:Oxygen